A multimodal digital microfluidic testing platform for antibody-producing cell lines.

Autor:	Lant JT; Department of Chemistry, University of Toronto, Toronto, Ontario, Canada. aaron.wheeler@utoronto.ca.; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada., Frasheri J; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada.; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada., Kwon T; Sartorius Stedim North America Inc., Marlborough, MA, USA., Tsang CMN; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada., Li BB; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada.; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada., Decombe S; Department of Chemistry, University of Toronto, Toronto, Ontario, Canada. aaron.wheeler@utoronto.ca.; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada., Sklavounos AA; Department of Chemistry, University of Toronto, Toronto, Ontario, Canada. aaron.wheeler@utoronto.ca.; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada., Akbari S; Sartorius Stedim North America Inc., Marlborough, MA, USA., Wheeler AR; Department of Chemistry, University of Toronto, Toronto, Ontario, Canada. aaron.wheeler@utoronto.ca.; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada.; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
Jazyk:	angličtina
Zdroj:	Lab on a chip [Lab Chip] 2024 Nov 20. Date of Electronic Publication: 2024 Nov 20.
DOI:	10.1039/d4lc00816b
Abstrakt:	In recent years, monoclonal antibodies (mAbs) have become a powerful tool in the treatment of human diseases. Currently, over 100 mAbs have received approval for therapeutic use in the US, with wide-ranging applications from cancer to infectious diseases. The predominant method of producing antibodies for therapeutics involves expression in mammalian cell lines. In the mAb production process, significant optimization is typically done to maximize antibody titres from cells grown in bioreactors. Therefore, systems that can miniaturize and automate cell line testing ( e.g. , viability and antibody production assays) are valuable in reducing therapeutic mAb development costs. Here we present a novel platform for cell line optimization for mAb production using digital microfluidics. The platform enables testing of cell culture samples in 6-8 μL droplets with semi-automated viability, media pH, and antibody production assays. This system provides a unique bridge between cell growth and productivity metrics, while minimizing culture volume requirements for daily testing. We propose that this technology and its future iterations has the potential to help reduce the time-to-market and development costs of antibody-producing cell lines.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu